title: Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer.
abstract: BACKGROUND
  TRPS-1 is a new GATA transcription factor that is differentially expressed in breast cancer (BC) where it been found recently to regulate epithelial-to-mesenchymal transition (EMT).
  
  
  METHODS
  We carried out a quantitative immunohistochemistry (qIHC) analysis of TRPS-1 expression in 341 primary-stage I-III BC samples in relation to patient clinical characteristics as well as its prognostic value, especially in an estrogen receptor-positive (ER+) subgroup.
  
  
  RESULTS
  Higher TRPS-1 expression was significantly associated with a number of clinical and pathological characteristics as well as with improved overall survival (OS) and disease-free survival (DFS). Among stage I/II ER+ BC patients who received endocrine therapy alone, those with high TRPS-1 expression had significantly longer OS and DFS. There was also a strong association between TRPS-1 levels and the EMT marker E-cadherin in the ER+ invasive ductal carcinoma cases. Analysis of gene expression data on a panel of BC lines found that TRPS-1 expression was low or absent in BC lines having enriched mesenchymal features.
  
  
  CONCLUSIONS
  Our data indicated that TRPS-1 is an independent prognostic marker in early-stage BC and a new EMT marker that can distinguish patients with ER+ BC who will respond longer to adjuvant endocrine therapy.
authors.affiliation: Departments of Breast Medical Oncology; Melanoma Medical Oncology.
authors.forename: J Q
authors.initials: JQ
authors.lastname: Chen
authors.affiliation: Departments of Breast Medical Oncology; Melanoma Medical Oncology.
authors.forename: Y
authors.initials: Y
authors.lastname: Bao
authors.affiliation: Systems Biology.
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.affiliation: Departments of Breast Medical Oncology.
authors.forename: J L
authors.initials: JL
authors.lastname: Murray
authors.affiliation: Departments of Breast Medical Oncology.
authors.forename: J K
authors.initials: JK
authors.lastname: Litton
authors.affiliation: Pathology, UT MD Anderson Cancer Center, Houston, USA; Department of Pathology, Shanghai Huadong Hospital, Shanghai, China.
authors.forename: L
authors.initials: L
authors.lastname: Xiao
authors.affiliation: Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston.
authors.forename: R
authors.initials: R
authors.lastname: Zhou
authors.affiliation: Pathology, UT MD Anderson Cancer Center, Houston, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Pathology, Veterans Administration Hospital, Baylor College of Medicine, Houston, USA.
authors.forename: X Y
authors.initials: XY
authors.lastname: Shen
authors.affiliation: Pathology, UT MD Anderson Cancer Center, Houston, USA.
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Pathology, UT MD Anderson Cancer Center, Houston, USA.
authors.forename: A A
authors.initials: AA
authors.lastname: Sahin
authors.affiliation: Pathology, UT MD Anderson Cancer Center, Houston, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Katz
authors.affiliation: Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston.
authors.forename: M L
authors.initials: ML
authors.lastname: Bondy
authors.affiliation: Sunnybrook Health Sciences Center, Toronto, Canada.
authors.forename: N L
authors.initials: NL
authors.lastname: Berinstein
authors.affiliation: Departments of Breast Medical Oncology.
authors.forename: G N
authors.initials: GN
authors.lastname: Hortobagyi
authors.affiliation: Departments of Breast Medical Oncology; Melanoma Medical Oncology. Electronic address: lradvanyi@mdanderson.org.
authors.forename: L G
authors.initials: LG
authors.lastname: Radvanyi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D015820:Cadherins / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D018572:Disease-Free Survival; D058750:Epithelial-Mesenchymal Transition; D047628:Estrogen Receptor alpha / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D019394:Ki-67 Antigen / Q000378:metabolism; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012097:Repressor Proteins; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D004268:DNA-Binding Proteins; D047628:Estrogen Receptor alpha; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011980:Receptors, Progesterone; D012097:Repressor Proteins; D014157:Transcription Factors; C108387:TRPS1 protein, human; C508053:ERBB2 protein, human
keywords: TRPS-1; breast cancer; immunohistochemistry; prognostic marker